Failure to Attain HIV Viral Suppression After Intensified Adherence Counselling—What Can We Learn About Its Factors?

References

• Global A, Sedai A, Ankita K. Statistics, global information and education on HIV and AIDS. JMIR Med Inform. 2019;7(1). doi:10.2196/medinform.9291
   Google Scholar
• Quinn TC. HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS. 2008;22(Suppl 3):S7. doi:10.1097/01.aids.0000327510.68503.e8
   PubMed Web of Science ®Google Scholar
• Slaymaker E, Todd J, Marston M, et al. How have ART treatment programmes changed the patterns of excess mortality in people living with HIV? Estimates from four countries in East and Southern Africa. Glob Health Action. 2014;7(1):22789. doi:10.3402/gha.v7.22789
   PubMed Web of Science ®Google Scholar
• Frank TD, Carter A, Jahagirdar D, et al. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019;6(12):e831–e859. doi:10.1016/S2352-3018(19)30196-1
   PubMed Web of Science ®Google Scholar
• Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS Res Palliat Care. 2012;117–124. doi:10.2147/HIV.S32321
   Google Scholar
• Marsh K, Eaton JW, Mahy M, et al. Global, regional and country-level 90–90–90 estimates for 2018: assessing progress towards the 2020 target. AIDS. 2019;33(Suppl 3):S213. doi:10.1097/QAD.0000000000002355
   PubMedGoogle Scholar
• Kyaw NTT, Harries AD, Kumar AMV, et al. High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005–2015. PLoS One. 2017;12(2):e0171780. doi:10.1371/journal.pone.0171780
   PubMed Web of Science ®Google Scholar
• Leng X, Liang S, Ma Y, et al. HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China. BMJ open. 2014;4(10):e005886. doi:10.1136/bmjopen-2014-005886
   PubMed Web of Science ®Google Scholar
• Yuan D, Liu M, Jia P, et al. Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study. BMC Infect Dis. 2020;20(1):1–10.
   Web of Science ®Google Scholar
• Joseph Davey D, Abrahams Z, Feinberg M, et al. Factors associated with recent unsuppressed viral load in HIV-1-infected patients in care on first-line antiretroviral therapy in South Africa. Int J STD AIDS. 2018;29(6):603–610. doi:10.1177/0956462417748859
   PubMed Web of Science ®Google Scholar
• Hicham T, Ilyas E, Tarik H, et al. Risk factors associated with unsuppressed viral load in HIV-1 infected patients at the first antiretroviral therapy in Morocco. Int J Mycobacteriol. 2019;8(2):113. doi:10.4103/ijmy.ijmy_41_19
   PubMed Web of Science ®Google Scholar
• Rangarajan S, Colby DJ, Giang LT, et al. Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J Virus Erad. 2016;2(2):94–101. doi:10.1016/S2055-6640(20)30466-0
   PubMed Web of Science ®Google Scholar
• Waju B, Dube L, Ahmed M, et al. Unsuppressed viral load level in public health facilities: nonvirological predictors among adult antiretroviral therapy users in southwestern Ethiopia. HIV/AIDS Res Palliat Care. 2021;Volume 13:513–526. doi:10.2147/HIV.S304653
   Google Scholar
• Mwangi A, van Wyk B. Factors associated with viral suppression among adolescents on antiretroviral therapy in Homa Bay County, Kenya: a retrospective cross-sectional study. HIV/AIDS Res Palliat Care. 2021;Volume 13:1111–1118. doi:10.2147/HIV.S345731
   Google Scholar
• Wang Y, Barnhart S, Francois K, et al. Expanded access to viral load testing and use of second line regimens in Haiti: time trends from 2010–2017. BMC Infect Dis. 2020;20(1):1–13.
   Web of Science ®Google Scholar
• Gunda DW, Kilonzo SB, Mtaki T, et al. Magnitude and correlates of virological failure among adult HIV patients receiving PI based second line ART regimens in north western Tanzania; a case control study. BMC Infect Dis. 2019;19(1):1–7. doi:10.1186/s12879-019-3852-3
   PubMedGoogle Scholar
• Kazooba P, Mayanja BN, Levin J, et al. Virological failure on first-line antiretroviral therapy; associated factors and a pragmatic approach for switching to second line therapy–evidence from a prospective cohort study in rural South-Western Uganda, 2004–2011. Pan Afr Med J. 2018;29(1):1–16. doi:10.11604/pamj.2018.29.191.11940
   PubMedGoogle Scholar
• Kiweewa F, Esber A, Musingye E, et al. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study. PLoS One. 2019;14(2):e0211344. doi:10.1371/journal.pone.0211344
   PubMed Web of Science ®Google Scholar
• Heath K, Levi J, Hill A. The Joint United Nations Programme on HIV/AIDS 95–95–95 targets: worldwide clinical and cost benefits of generic manufacture. AIDS. 2021;35(1):S197–S203. doi:10.1097/QAD.0000000000002983
   PubMedGoogle Scholar
• Ramadhani A, Josiah RM, Rwebembera A, et al. National Guidelines for the Management of HIV and AIDS. Ministry of Health and Social Welfare; 2012.
   Google Scholar
• Kroidl A, Burger T, Urio A, et al. High turnaround times and low viral resuppression rates after reinforced adherence counselling following a confirmed virological failure diagnostic algorithm in HIV‐infected patients on first‐line antiretroviral therapy from Tanzania. Trop Med Int Health. 2020;25(5):579–589. doi:10.1111/tmi.13373
   PubMed Web of Science ®Google Scholar
• Collins IJ, Wools-Kaloustian K, Goodall R, et al. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. Lancet HIV. 2019;6(2):e105–e115. doi:10.1016/S2352-3018(18)30319-9
   PubMed Web of Science ®Google Scholar
• Hawkins C, Hertzmark E, Spiegelman D, et al. Switching to second-line ART in relation to mortality in a large Tanzanian HIV cohort. J Antimicrob Chemother. 2017;72(7):2060–2068. doi:10.1093/jac/dkx098
   PubMed Web of Science ®Google Scholar
• Ssempijja V, Nakigozi G, Chang L, et al. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda. BMC Infect Dis. 2017;17(1):1–10. doi:10.1186/s12879-017-2680-6
   PubMedGoogle Scholar
• Ramadhani HO, Bartlett JA, Thielman NM, et al. The effect of switching to second-line antiretroviral therapy on the risk of opportunistic infections among patients infected with human immunodeficiency virus in northern Tanzania. In: Open Forum Infectious Diseases. Oxford University Press; 2016.
   Google Scholar
• Simon R, Gilyoma JM, Dass RM, et al. Paediatric injuries at Bugando Medical Centre in Northwestern Tanzania: a prospective review of 150 cases. J Trauma Manag Outcomes. 2013;7(1):1–9. doi:10.1186/1752-2897-7-10
   PubMedGoogle Scholar
• Moremi N, Claus H, Vogel U, et al. Surveillance of surgical site infections by Pseudomonas aeruginosa and strain characterization in Tanzanian hospitals does not provide proof for a role of hospital water plumbing systems in transmission. Antimicrob Resist Infect Control. 2017;6(1):1–8. doi:10.1186/s13756-017-0216-x
   Google Scholar
• Yonah G, Fredrick F, Leyna G. HIV serostatus disclosure among people living with HIV/AIDS in Mwanza, Tanzania. AIDS Res Ther. 2014;11(1):1–5. doi:10.1186/1742-6405-11-5
   PubMedGoogle Scholar
• World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. World Health Organization; 2016.
   Google Scholar
• Wu P, Johnson B, Nachega J, et al. The combination of pill count and self-reported adherence is a strong predictor of first-line ART failure for adults in South Africa. Curr HIV Res. 2014;12(5):366–375. doi:10.2174/1570162X1205141121102501
   PubMed Web of Science ®Google Scholar
• Anuradha S, Joshi A, Negi M, et al. Factors influencing adherence to ART: new insights from a center providing free ART under the national program in Delhi, India. J Int Assoc Provid AIDS Care. 2013;12(3):195–201. doi:10.1177/1545109711431344
   PubMedGoogle Scholar
• Lee SB, Valerius J. Valerius, mHealth interventions to promote anti-retroviral adherence in HIV: narrative review. JMIR mHealth and uHealth. 2020;8(8):e14739. doi:10.2196/14739
   PubMed Web of Science ®Google Scholar
• Mwangi A, Wanzala P, Karanja S, Karanja SM. Factors influencing adherence to ARVS among patients attending comprehensive care clinic within Jomo Kenyatta University of Agriculture and Technology, Kiambu County, Kenya. East Afr Med J. 2014;91(4):109–114.
   PubMedGoogle Scholar
• Kipsang J, Chen J, Tang C, et al. Self reported adherence to antiretroviral treatment and correlates in Hunan province, the Peoples Republic of China. Int J Nurs Sci. 2018;5(2):162–167. doi:10.1016/j.ijnss.2018.04.008
   PubMed Web of Science ®Google Scholar
• Nachega B, Marconi V, van Zyl G, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011;11(2):167–174. doi:10.2174/187152611795589663
   PubMedGoogle Scholar
• Fentie Wendie T, Workneh BD. Prevalence and predictors of virological failure among adults living with HIV in South Wollo Zone, Northeast Ethiopia: a retrospective cohort study. HIV/AIDS Res Palliat Care. 2020;12:393–402. doi:10.2147/HIV.S266460
   Google Scholar
• Meshesha HM, Nigussie ZM, Asrat A, et al. Determinants of virological failure among adults on first-line highly active antiretroviral therapy at public health facilities in Kombolcha town, Northeast, Ethiopia: a case–control study. BMJ open. 2020;10(7):e036223. doi:10.1136/bmjopen-2019-036223
   PubMed Web of Science ®Google Scholar
• Abdullahi IJ, Deybasso HA, Adlo AM. Determinants of virological failure among patients on first-line antiretroviral therapy in central Oromia, Ethiopia: a case–control study. HIV/AIDS Res Palliat Care. 2020;12:931–939. doi:10.2147/HIV.S281672
   Google Scholar
• Ndahimana JDA, Riedel DJ, Mwumvaneza M, et al. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda. Trop Med Int Health. 2016;21(7):928–935. doi:10.1111/tmi.12717
   PubMed Web of Science ®Google Scholar
• Lailulo Y, Kitenge M, Jaffer S, et al. Factors associated with antiretroviral treatment failure among people living with HIV on antiretroviral therapy in resource-poor settings: a systematic review and metaanalysis. Syst Rev. 2020;9(1):1–17. doi:10.1186/s13643-020-01524-1
   PubMed Web of Science ®Google Scholar
• Emagnu A, Abay Z, Bulti AB, et al. Determinants of virologic failure among adult HIV patients on first-line antiretroviral therapy at waghimra zone, northern Ethiopia: a case-control study. Adv Public Health. 2020;2020:1–8. doi:10.1155/2020/1929436
   Google Scholar
• Martelli G, Antonucci R, Mukurasi A, et al. Adherence to antiretroviral treatment among children and adolescents in Tanzania: comparison between pill count and viral load outcomes in a rural context of Mwanza region. PLoS One. 2019;14(3):e0214014. doi:10.1371/journal.pone.0214014
   PubMed Web of Science ®Google Scholar